S100B and myeloid sarcoma: Curiously, S100B levels are significantly reduced in response to MS treatments such as mitoxantrone (Bartosik-Psujek et al., 2011) and nataluzimab (O’Connell et al., 2014), suggestive of an important role during MS pathogenesis.